Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status.

Kamil Demircan, Thilo Samson Chillon, Qian Sun, Raban Arved Heller, Georg Jochen Klingenberg, Ines Maria Hirschbil-Bremer, Petra Seemann, Joachim Diegmann, Manuel Bachmann, Arash Moghaddam, Lutz Schomburg

Journal: Redox biology 2022;50():102242

PMID: 35139480

Free Full Text on Elsevier Science View on PubMed

Abstract

The essential trace element selenium (Se) is of central importance for human health and particularly for a regular functioning of the immune system. In the context of the current pandemic, Se deficiency in patients with COVID-19 correlated with disease severity and mortality risk. Selenium has been reported to be associated with the immune response following vaccination, but it is unknown whether this also applies to SARS-CoV-2 vaccines. In this observational study, adult health care workers (n = 126) who received two consecutive anti-SARS-CoV-2 vaccinations by BNT162b2 were followed for up to 24 weeks, with blood samples collected at the first and second dose and at three and 21 weeks after the second dose. Serum SARS-CoV-2 IgG titres, neutralising antibody potency, total Se and selenoprotein P concentrations, and glutathione peroxidase 3 activity were quantified. All three biomarkers of Se status were significantly correlated at all the time points, and participants who reported supplemental Se intake displayed higher Se concentrations. SARS-CoV-2 IgG titres and neutralising potency were highest three weeks after the second dose and decreased towards the last sampling point. The humoral immune response was not related to any of the three Se status biomarkers. Supplemental Se intake had no effect at any time point on the vaccination response as measured by serum SARS-CoV-2 IgG levels or neutralising potency. Overall, no association was found between Se status or supplemental Se intake and humoral immune response to COVID-19 mRNA vaccination.

Address: Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-10115 Berlin, Germany; Berlin Institute of Health (BIH), Biomedical Innovation Academy (BIA), D-10117 Berlin, Germany.; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-10115 Berlin, Germany.; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-10115 Berlin, Germany; Bundeswehr Hospital Berlin, Clinic of Traumatology and Orthopaedics, D-10115 Berlin, Germany; Department of General Practice and Health Services Research, Heidelberg University Hospital, D-69120 Heidelberg, Germany.; ATORG, Aschaffenburg Trauma and Orthopaedic Research Group, Center for Orthopaedics, Trauma Surgery and Sports Medicine, Hospital Aschaffenburg-Alzenau, D-63739 Aschaffenburg, Germany.; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-10115 Berlin, Germany; selenOmed GmbH, D-10965 Berlin, Germany.; Orthopedic and Trauma Surgery, Frohsinnstraße 12, D-63739 Aschaffenburg, Germany.; Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, D-10115 Berlin, Germany. Electronic address: [email protected].

DOI: 10.1016/j.redox.2022.102242

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/covid19coronavirusdisease2...

Miscellaneous:

https://assays.cancer.gov/CPTAC-438

MeSH Terms: Adult, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Humans, Immunity, Humoral, RNA, Messenger, SARS-CoV-2, Selenium, Vaccination